Watch the recording of webinar “AL amyloidosis treatment updates and patient experiences”

AL amyloidosis, MPELeave a comment

  Myeloma Patients Europe (MPE) held a webinar to summarise the most important AL amyloidosis updates and share patient experiences with therapies like CAR-T and CAEL-101.  The webinar took place on 16th April 2024 and was given by Dr. Moshe Gatt, Physician Researcher Haematologist at the Hebrew University of Jerusalem, Israel, along with two AL Amyloidosis patients from Israel, Naphtali Mastboim and Melvin Granatstein. Watch the recording below:  

MPE launches the Myeloma and AL Amyloidosis European Clinical Trial Navigator

Access, AL amyloidosis, MPE, MyelomaLeave a comment

  Brussels, 23 April 2024 – Myeloma Patients Europe (MPE) has launched today the English version of the Myeloma and AL Amyloidosis European Clinical Trial Navigator, an online search tool to learn about and find clinical trials for myeloma, monoclonal gammopathy of undetermined significance (MGUS), smouldering multiple myeloma (SMM) and AL amyloidosis in Europe. With this tool, MPE wants to facilitate the search of clinical trials for these conditions and provide to patients, carers and…

Sign up for the MPE webinar “AL amyloidosis treatment updates and patient experiences on new therapies”

AL amyloidosis, MPELeave a comment

  Myeloma Patients Europe (MPE) will hold the webinar “AL amyloidosis treatment updates and patient experiences on new therapies” on Tuesday 16 April from 17:00 – 18:00 CEST. The webinar will be given by Dr. Moshe Gatt, Physician Researcher Haematologist at the Hebrew University of Jerusalem, Israel, along with two AL Amyloidosis patients from Israel, Naphtali Mastboim and Melvin Granatstein, who will share their experiences with new therapies like CAR-T and CAEL-101. If you would…

ASH 2023 | Myeloma and AL amyloidosis updates

AL amyloidosis, CAR-T, Conferences, MPE, MyelomaLeave a comment

Myeloma Patients Europe (MPE) attended the 65th American Society of Hematology (ASH) Annual Meeting, the largest haematology congress, held from 9 to 12 December in San Diego (United States). MPE has interviewed haematology experts to summarise the latest myeloma and AL amyloidosis updates.     Prof. Dr. Michel Delforge, Department of Haematology, University Hospital Leuven, Belgium, explains the latest findings on the KarMMa-3 trial and the impact abecma has on Quality of Life (QoL) presented at…

Sign up for the MPE webinar on ASH 2023 myeloma and AL amyloidosis highlights

AL amyloidosis, CAR-T, Conferences, MPE, Myeloma, NewsLeave a comment

Myeloma Patients Europe (MPE) will host a webinar to summarise the most important myeloma and AL amyloidosis updates presented at the 65th American Society of Hematology (ASH) Annual Meeting which will be held 9-12 December, 2023 in San Diego, California, United States.   The webinar will take place on Wednesday, 17 January from 17:00 to 18:00 CET and will be given by Dr. Faith Davies, Director of Clinical Myeloma Programme at NYU Langone Health Perlmutter…

Myeloma and AL amyloidosis ASH 2023 preview

AL amyloidosis, Conferences, MyelomaLeave a comment

    The American Society of Hematology (ASH) Annual Meeting, the world’s largest haematology conference, will take place from 9 – 12 December in San Diego, United States. It is a very exciting event for the myeloma and AL amyloidosis clinical and patient community, with all the results from the latest and most important research being presented. Myeloma Patients Europe (MPE) will attend the meeting to learn and share updates about the most significant developments…

MPE launches a report focused on the impact of AL amyloidosis in quality of life

AL amyloidosis, MPELeave a comment

AL amyloidosis is a rare condition and limited research on patient perspectives and needs exists. With the aim to better understand patients’ experiences regarding AL amyloidosis diagnosis and treatment, and how these impact on quality of life, MPE conducted qualitative research and published the report “Health-related quality of life, diagnosis and treatment experiences of AL amyloidosis patients.” According to this report, “receiving a diagnosis of AL amyloidosis can make people feel as if they have…

MPE launches European Amyloidosis Diagnosis Pathway to promote early detection of the rare disease

Access, AL amyloidosisLeave a comment

Today, 26 October 2023, is World Amyloidosis Day, a day dedicated to raising awareness about the rare disease amyloidosis and the key issues and challenges for patients. A central theme for the day, organised by the Amyloidosis Alliance, alongside amyloidosis patient organisations from across the globe, is improving the diagnosis experience of patients. Amyloidosis is a group of rare, serious conditions caused by a build-up of an abnormal protein called amyloid in organs and tissues…

Watch the recording of the EHA 2023 highlights webinar

AL amyloidosis, MPE, Myeloma, VideosLeave a comment

Myeloma Patients Europe (MPE) held a webinar to summarise the most important myeloma and AL amyloidosis updates presented at the European Hematology Association (EHA) hybrid 2023 congress. This congress was held in Frankfurt, Germany, in June 2023. The webinar took place on 6th July 2023 and was given by Prof. Dr. Mohamad Mohty, Professor and Head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and Sorbonne University (Paris, France), who delivered a…